Release Date: 27/10/14 17:28 Summary: Third Supplementary Bidder's Statement Price Sensitive: Yes Download Document 158.55KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%